Identifying insulin treatment responders with a composite measure: beyond Hba1c < 7% in patients with type 2 diabetes

References

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, standards of medical care in diabetes. Diabetes Care 2017;40(supp. 1):S1-S120
   PubMedGoogle Scholar
• Guigliano D, Maiorino MI, Bellastella G, et al. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diab Clin Res Prac 2011;92:1-10
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diab Obes Metab 2012;14:228-33
   PubMed Web of Science ®Google Scholar
• The National Committee for Quality Assurance (NCQA). Comprehensive diabetes care. Available at: http://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality/2016-table-of-contents/diabetes-care. [Last accessed 19 September 2017]
   Google Scholar
• Nathan DM, DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-88
   PubMed Web of Science ®Google Scholar
• DCCT Research Group. The association between glycemic exposure and long term diabetic complications in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-83
   PubMed Web of Science ®Google Scholar
• Nathan DM, Bayless M, Cleary P, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013;62:3976-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321:405-41
   PubMed Web of Science ®Google Scholar
• Fu H, Cao D, Boye KS, et al. Early glycemic response predicts achievement of subsequent treatment targets in the treatment of type 2 diabetes: a post hoc analysis. Diabetes Ther 2015;6:317-28
   PubMed Web of Science ®Google Scholar
• Kerr EA, Krein SL, Vijan S, et al. Avoiding pitfalls in chronic disease quality measurement: a case for the next generation of technical quality measures. Am J Manag Care 2001;7:1033-43
   PubMed Web of Science ®Google Scholar
• O’Connor PJ, Bodkin NL, Fradkin J, et al. Diabetes performance measures: current status and future directions. Diabetes Care 2011;34:1651-9
   PubMed Web of Science ®Google Scholar
• Riddle MC, Vlajnic A, Zhou R, et al. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diab Obes Metab 2013;15:819-25
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabetic Med 2010;27:309-17
   PubMed Web of Science ®Google Scholar
• Hall GC, McMahon AD, Carroll D, et al. Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. PLoS One 2012;11:1-7
   Google Scholar
• Drake TC, Hsu F-C, Hire D, et al. Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diab Obes Metab 2016;18:92-5
   PubMed Web of Science ®Google Scholar
• Balkau B, Calvi-Gries F, Freemantle N, et al. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study. Diab Res Clin Prac 2015;108:432-40
   PubMed Web of Science ®Google Scholar
• Owen V, Seetho I, Idris I. Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. Diab Obes Metab 2010;12:865-70
   PubMed Web of Science ®Google Scholar
• Ball WL, Godsby MJ, Nicholas A, et al. Redesigning the health care team: Diabetes prevention and lifelong management. NIH Publication No. 11-7739 NDEP-37. Bethesda, MD: National Diabetes Education Program; Revised June 2011
   Google Scholar
• Del Prato S, Felton AM, Munro N, et al. Global partnership for effective diabetes management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345-55
   PubMed Web of Science ®Google Scholar
• Curtis B, Lage M. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 2014;17:21-31
   PubMedGoogle Scholar
• Wolffenbuttel B, Sels J, Rondas-Colbers G, et al. Prognostic factors for successful insulin therapy in patients with type 2 diabetes. Nether J Med 1999;54:63-9
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fleischmann H, Schiffhorst G, et al. Predictors of response to early basal insulin treatment in patients with type 2 diabetes–the EARLY experience. Diabetes Technol Ther 2014;6:241-6
   Web of Science ®Google Scholar
• Valensi P, Shaban J, Benroubi M, et al. and IMPROVE Study Expert Panel. Predictors of achieving HbA1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study. Curr Med Res Opin 2013;29:601-9
   PubMed Web of Science ®Google Scholar
• Davidson JA, Wolffenbuttel BA, Arakaki RF, et al. Impact of race/ethnicity on efficacy and safety of two starter insulin regimens in patients with type 2 diabetes: a posthoc analysis of the DURABLE trial. Ethn Dis 2013;23:393-40
   PubMed Web of Science ®Google Scholar
• Jia W, Xiao X, Ji Q, et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in East Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol 2015;3:254-62
   PubMed Web of Science ®Google Scholar